FDA Grants Fast Track Designation for Remestemcel-L in the Treatment of ...
Mesoblast Limited received FDA Fast Track designation for remestemcel-L to treat COVID-19 induced ARDS, aiming to expedite therapy development. A Phase 3 trial is ongoing, with promising results from a pilot study showing 75% of ventilator-dependent patients discharged after treatment. Mesoblast collaborates with Novartis for remestemcel-L's development.
Reference News
FDA Grants Fast Track Designation for Remestemcel-L in the Treatment of ...
Mesoblast Limited received FDA Fast Track designation for remestemcel-L to treat COVID-19 induced ARDS, aiming to expedite therapy development. A Phase 3 trial is ongoing, with promising results from a pilot study showing 75% of ventilator-dependent patients discharged after treatment. Mesoblast collaborates with Novartis for remestemcel-L's development.